This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week, we will discuss some groundbreaking work on elucidating the adaptive and maladaptive cellular transcription and gene activation of the kidney in healthy and diseased states.
Glomeruli seem fun and interesting, but the final common pathway for all kidney diseases is fibrosis. Irreversible and relentless once it sets in. Here we discuss some meticulous and groundbreaking work on how this develops, using really cool techniques.
This week, we will discuss the fresh-off-the-press trials from this week’s issue of the NEJM: PERL and CKD-FiX. These two trials examined if the uric acid and CKD link is causal: by measuring CKD progression after giving patients allopurinol. Be ready for another medical reversal.
SGLT2i are the wonder drug for our age. But do we know how they work? How does their natriuretic effect actually work? Let’s dig deeper into this week’s mechanistic study that explores this question